Arcus Biosciences, Inc. (RCUS) SEC Filings & Earnings Calls

Dilution risk from significant share issuance.

“Issuance of 16,428,572 shares of common stock.”

Preliminary estimate subject to adjustment; no audited financials provided.

“This estimate of its cash, cash equivalents and marketable securities balance is preliminary and subject to completion of the Company’s financial closing procedures” · word for word

Clinical trial data is early-stage with small sample sizes; regulatory approval and commercial success are uncertain.

“Small sample sizes (n=30, n=31, n=43, n=121) and early follow-up in some cohorts.”

Dependence on Gilead partnership for funding and pipeline development

“Gilead and the Issuer entered into an Option, License and Collaboration Agreement ... Gilead obtained an exclusive option to acquire an exclusive license to all of the Issuer's current and future clinical programs” · word for word

Option to purchase additional shares expired, limiting future equity investment from Gilead

“On July 13, 2025, Gilead's option to purchase additional shares from the Issuer, up to a maximum of 35% of the Issuer's then-outstanding Common Stock, expired.” · word for word

Clinical-stage company with no approved products; dependency on pipeline success.

“clinical-stage, global biopharmaceutical company” · word for word

Clinical trial failure risk

“the Phase 3 STAR-221 was discontinued after our interim analysis in December 2025 showed no benefit over standard of care.” · word for word

No approved products / no revenue

“We are a clinical-stage biopharmaceutical company with a limited operating history... none have been approved for commercial sale, nor have we ever generated any revenue from product sales.” · word for word

Need for additional funding

“We may need to obtain additional funding. If we do not receive or are unable to raise additional capital when needed, we may be forced to restrict our operations or delay, reduce or eliminate our product development programs.” · word for word

Debt covenant restrictions

“The Hercules Agreement, as amended, subjects us to various customary covenants, including, among other things, requirements as to financial reporting and minimum cash (beginning July 2027) and net product revenue (following achievement of certain regulatory milestones)...” · word for word

Phase 3 trial failure

“In April 2026, we announced the discontinuation of the Phase 3 STAR-121 study due to futility.” · word for word

Collaboration dependency and reduction

“Following Gilead’s decision to not make the option continuation payment due on the sixth anniversary, on July 14, 2026, Gilead will lose certain rights to access and obtain licenses to the programs arising from our R&D pipeline.” · word for word

China supply chain risk

“WuXi Biologics, located in China, is currently our sole manufacturer of zimberelimab and domvanalimab. If WuXi Biologics becomes subject to trade restrictions, sanctions, increased tariffs or other regulatory requirements by the U.S. government (including designation as a "biotechnology company of concern" under the U.S. BIOSECURE Act)... it could materially” · word for word

No product revenue and history of losses

“We have a history of operating losses, have never generated any revenue from product sales and anticipate that we will continue to incur significant losses for the foreseeable future.” · word for word

Debt covenant restrictions

“Our operating activities may be restricted as a result of covenants related to the indebtedness under our loan and security agreement with Hercules Capital, Inc., as amended, and we may be required to repay the outstanding indebtedness in an event of default, which could have a materially adverse effect on our business.” · word for word

Phase 3 STAR-121 trial failure in NSCLC represents a significant pipeline setback, reducing probability of success for domvanalimab franchise.

“Arcus announced the discontinuation of the Phase 3 STAR-121 study... based on the recommendation from the Independent Data Monitoring Committee following its review of data from a pre-planned futility analysis.” · word for word

Casdatifan development is still early-stage with no approved product; regulatory and clinical risks remain high.

“Casdatifan is in Phase 1/1b and Phase 3 studies; no regulatory approvals yet.”

Phase 3 trial futility

“In December 2025, we announced the discontinuation of STAR-221 due to futility. A futility analysis is being conducted for STAR-121 with results expected in the first-half of 2026.” · word for word

Dependence on Gilead collaboration

“Gilead Sciences, Inc. 31,424,960 shares, 25.1% beneficial ownership. Gilead’s current director designees are Dr. Berger, Dr. Higgins and Ms. Mercier.”

Net loss and cash burn

“Net income (353) ($ millions) for 2025.”

Clinical trial failure for lead program; loss of Gilead option rights reduces future collaboration opportunities.

“STAR-121 discontinued due to futility; Gilead option rights ending.”

Loss of COO may impact operational execution; transition risk.

“Resignation of Chief Operating Officer.”

Phase 3 STAR-221 futility failure

“In December 2025, we announced the discontinuation of the Phase 3 STAR-221 study... due to futility.” · word for word

eVOLVE-RCC02 pause due to immune AEs

“In October 2025, we announced eVOLVE-RCC02... has paused recruitment.” · word for word

Gilead returned etrumadenant license

“In June 2025, Gilead returned its license to the adenosine receptor antagonist program.” · word for word

No approved products; no product revenue

“We have not generated any revenue from product sales and do not expect to generate any revenue from product sales for the foreseeable future.” · word for word

Domvanalimab program discontinuation in gastric cancer; uncertainty in lung cancer.

“Winding down STAR-221 and EDGE-Gastric studies; futility analysis for STAR-121 upcoming.”

Pre-revenue with significant cash burn; reliance on pipeline success.

“No revenue mentioned; cash burn from R&D and G&A expenses.”

Clinical and regulatory milestones are required to access a portion of the funds, introducing execution risk.

“Tranches contingent on Phase 3 data and FDA approval; performance covenants if debt exceeds $200M.”

Key pipeline asset (domvanalimab) fails in Phase 3; significant setback for immuno-oncology strategy.

“STAR-221 study discontinued due to futility; domvanalimab-based combination did not improve OS.”

Significant dilution from 15.755M new shares; potential downward pressure on stock price.

“sale and issuance of an aggregate of 15,755,000 shares of Common Stock” · word for word

No approved products and history of losses

“We are a clinical-stage biopharmaceutical company with a limited operating history... All of our investigational products are in development, and none have been approved for commercial sale, nor have we ever generated any revenue from product sales.” · word for word

Dependence on Gilead collaboration

“Our strategy for fully developing and commercializing our investigational products is dependent upon maintaining our current arrangements with Gilead and our other strategic partners.” · word for word

Single source manufacturing in China

“WuXi Biologics, located in China, is currently our sole manufacturer of zimberelimab and domvanalimab.” · word for word

Clinical trial risk: potential immune-mediated adverse events observed in eVOLVE-RCC02 study led to temporary pause.

“Following observations of potential immune-mediated adverse events, none of which exceeded Grade 3, a decision was made to temporarily pause recruitment.” · word for word